Recently, researchers from New York have modified chimeric antigen receptor T cells (CAR-T) to secrete PD-1 blocked single-chain variable fragments (scFv); these scFv-secreting CAR-T cells play paracrine and autocrine roles to improve the antitumor activity of CAR-T cells and bystander tumor-specific T cells in syngeneic and xenogeneic mouse models of clinically relevant PD-L1+ hematological and solid tumors (143). This evidence concerns the gene CD274 and neoplasm.